RWJ 50271
RWJ 50271 is an selective and orally active inhibitor of lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 (LFA-1/ICAM-1) interaction with an IC50 of 5.0 μM (HL60 cells) . RWJ 50271 inhibits LFA-1/ICAM-1-mediated cell adhesion[1].
Product Specifications
CAS Number
[162112-37-0]
UNSPSC
12352005
Hazard Statement
H315, H319
Target
Integrin
Type
Reference compound
Related Pathways
Cytoskeleton
Applications
Neuroscience-Neuromodulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/rwj-50271.html
Concentration
10mM
Purity
99.25
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
CC1=C(C(NCCCO)=O)C=NN1C2=NC(C3=CC(C(F)(F)F)=CC=C3)=CS2
Molecular Formula
C18H17F3N4O2S
Molecular Weight
410.41
Precautions
H315, H319
References & Citations
[1]Sanfilippo PJ, et al. Novel thiazole based heterocycles as inhibitors of LFA-1/ICAM-1 mediated cell adhesion. J Med Chem. 1995 Mar 31;38 (7) :1057-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6159387-01 0.1 mL
PDZD8 (PDZ Domain-containing Protein 8, Sarcoma Antigen NY-SAR-84/NY-SAR-104, PDZK8, bA129M16.2, FLJ25412, FLJ34427) (PE)
Ask
View Details 
MBS6159387-02 5x 0.1 mL
PDZD8 (PDZ Domain-containing Protein 8, Sarcoma Antigen NY-SAR-84/NY-SAR-104, PDZK8, bA129M16.2, FLJ25412, FLJ34427) (PE)
Ask
View Details 